pexidartinib has been researched along with Mesothelioma* in 1 studies
1 other study(ies) available for pexidartinib and Mesothelioma
| Article | Year |
|---|---|
Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
New immunotherapeutic strategies are needed to induce effective antitumor immunity in all cancer patients. Malignant mesothelioma is characterized by a poor prognosis and resistance to conventional therapies. Infiltration of tumor-associated macrophages (TAM) is prominent in mesothelioma and is linked to immune suppression, angiogenesis, and tumor aggressiveness. Therefore, TAM depletion could potentially reactivate antitumor immunity. We show that M-CSFR inhibition using the CSF-1R kinase inhibitor PLX3397 (pexidartinib) effectively reduced numbers of TAMs, circulating nonclassical monocytes, as well as amount of neoangiogenesis and ascites in mesothelioma mouse models, but did not improve survival. When combined with dendritic cell vaccination, survival was synergistically enhanced with a concomitant decrease in TAMs and an increase in CD8 Topics: Aminopyridines; Animals; Antigens, Neoplasm; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Humans; Immunotherapy, Adoptive; Lung Neoplasms; Macrophages; Mesothelioma; Mesothelioma, Malignant; Neoplasm Invasiveness; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor | 2017 |